List of Topics | GCCM 2027

01 Topics

Every session topic at GCCM 2027.

A complete, searchable index of 98+ session topics across 14 scientific tracks. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

Interventional Cardiology

TAVR, complex PCI, structural heart and tricuspid/mitral interventions.

Track details

TAVR in low-risk, bicuspid, and small-annulus anatomy
Mitral and tricuspid TEER, replacement, and valve-in-MAC
OCT/IVUS-guided complex and bifurcation PCI (ILUMIEN IV, OCTOBER)
Coronary physiology: FFR, iFR, QFR and microvascular angina
LAA closure post-CHAMPION-AF and PFO closure post-RoPE
Chronic total occlusion: DECISION-CTO, EUROCTO and hybrid crossing algorithms
Catheter-directed pulmonary embolism therapy (HI-PEITHO)

02 Track

Heart Failure & Transplant

Four-pillar GDMT, vericiguat, LVADs and DCD heart transplantation.

Track details

Four-pillar GDMT and rapid sequencing protocols
Vericiguat (VICTOR) and finerenone (FINEARTS-HF) integration
HFpEF phenotyping and GLP-1 agonists (STEP-HFpEF, SUMMIT)
Acute HF: DAPA ACT HF-TIMI 68 and decongestion strategies
Mechanical circulatory support: HeartMate 3, Impella 5.5
DCD heart transplantation and donor pool expansion
HCM and ATTR-CM: mavacamten, aficamten, acoramidis, vutrisiran

03 Track

Electrophysiology

Pulsed field ablation, conduction system pacing and AI arrhythmia detection.

Track details

Pulsed field ablation: durability, persistent AF, VT applications
Conduction system pacing: His-bundle and LBBAP vs biventricular
Leadless pacemakers (AVEIR DR) and extravascular ICDs
VT ablation: substrate mapping and stereotactic radiotherapy
AI-ECG and wearable arrhythmia screening
Anticoagulation post-ablation: ALONE-AF and OPTION
SCD risk in non-ischemic cardiomyopathy

04 Track

Preventive Cardiology & Lipidology

Lp(a) lowering, PCSK9 trials, baxdrostat and residual risk.

Track details

Lp(a)-lowering: pelacarsen, olpasiran, lepodisiran, muvalaplin
PCSK9 and inclisiran: VESALIUS-CV in primary prevention
Olezarsen and APOC3-targeted hypertriglyceridemia therapy
Hypertension: baxdrostat (BaxHTN) and zilebesiran (KARDIA-3)
Colchicine and IL-6 inhibition: residual inflammatory risk
CAC, polygenic risk, and ancestry-aware ASCVD prediction
Renal denervation: post-approval real-world outcomes

05 Track

Cardiometabolic Medicine

GLP-1 agonists, obesity, diabetes-CV-kidney axis and CKM syndrome.

Track details

GLP-1 and dual agonists: SELECT, SURMOUNT-MMO, STEP-HFpEF, FLOW
Pipeline: retatrutide, orforglipron, survodutide
CKM syndrome: AHA staging and clinic operational models
Finerenone across diabetic CKD and HFpEF (FINEARTS-HF)
MASLD/MASH and cardiovascular risk
Obesity as a primary cardiovascular risk factor
Type 2 diabetes prevention and pre-diabetes management

06 Track

Cardio-Oncology

ICI myocarditis, CAR-T toxicity and surveillance imaging.

Track details

ICI myocarditis: ATRIUM, abatacept, ruxolitinib protocols
CAR-T cell therapy cardiovascular toxicity
Anthracycline and HER2 surveillance: GLS and CMR mapping
BTK and kinase inhibitors: AF and hypertension management
Radiation-induced coronary, valvular, and pericardial disease
Cancer-associated thrombosis and DOAC selection
Survivorship cardiology and primary-care interface

07 Track

Cardiac Imaging

Photon-counting CT, CMR mapping and AI-augmented echocardiography.

Track details

Photon-counting CT: coronary, stent, and TAVR planning
CCTA gatekeeping: FFR-CT, plaque burden, perivascular fat
CMR mapping: T1, T2, ECV in amyloid, myocarditis, sarcoid
AI echo: automated EF, strain, valve quantification
Hybrid PET-MR for sarcoidosis and infective endocarditis
Multimodality assessment of structural heart interventions
Imaging biomarkers in trials and registries

08 Track

Digital Health & AI in Cardiology

AI-ECG, wearables, foundation models and clinical implementation.

Track details

AI-ECG: low EF, amyloid, AS, hyperkalemia screening
AI structural-heart screening: PREVUE-VALVE, EchoNet
Wearables and consumer devices: AF, sleep, hemodynamics
Remote monitoring in HF: CardioMEMS and pressure sensors
Foundation models and multimodal cardiovascular AI
Implementation science: bias, dataset shift, governance
Reimbursement, regulation, and the FDA AI/ML pathway

09 Track

Critical Care Cardiology

Cardiogenic shock, mechanical support, ECMO and the modern CICU.

Track details

Cardiogenic shock: DanGer Shock, ECLS-SHOCK, SCAI staging
Impella, IABP, and VA-ECMO: selection and weaning
STEMI Door-to-Unload and pre-PCI mechanical support
Massive and submassive PE: HI-PEITHO, FlowTriever
Refractory ventricular arrhythmias in the CICU
Post-cardiac-arrest care and TTM-2 era protocols
Shock teams, regionalization, and CICU staffing models

10 Track

Pulmonary Hypertension & Right Heart

Sotatercept (STELLAR/CADENCE), CTEPH, BPA and right-heart imaging.

Track details

Sotatercept in PAH: STELLAR, CADENCE, ZENITH (Group 2)
Risk-stratified upfront combination therapy
CTEPH: balloon pulmonary angioplasty and PEA selection
Right ventricular imaging: CMR strain and 4D flow
Exercise hemodynamics and unmasking PH
Group 2 PH (HFpEF) and Group 3 PH (lung disease)
Lung transplantation referral in advanced PH

11 Track

Inflammatory, Pericardial & Myocarditis

ESC 2025 myocarditis guidelines, IL-1 inhibitors and infective endocarditis.

Track details

Myocarditis: ESC 2025 guidelines and Updated Lake Louise CMR
Recurrent pericarditis: rilonacept (RHAPSODY) and anakinra
Infective endocarditis: OPAT, POET oral step-down
Post-COVID and post-vaccine myocarditis cohorts
Cardiac sarcoidosis: PET-guided immunosuppression
Giant-cell and eosinophilic myocarditis
Chagas cardiomyopathy: PARACHUTE-HF and global burden

12 Track

Sports & Exercise Cardiology

Athlete screening, inherited arrhythmias and exercise prescription.

Track details

Pre-participation screening: ECG criteria, ESC vs AHA
Athlete's heart vs HCM, ARVC, and DCM
Inherited arrhythmias: LQTS, CPVT, Brugada in athletes
AF and coronary calcification in masters athletes
Return-to-play after myocarditis and SCD events
Exercise prescription in established CV disease
Shared decision-making and 2024 RTP guidelines

13 Track

Cardiovascular Genomics & Precision Medicine

Polygenic risk, FH, gene editing (VERVE-102) and clonal hematopoiesis.

Track details

VERVE-102 PCSK9 base editing and CRISPR cardiology
Familial hypercholesterolemia: cascade screening models
ATTR-CM: NTLA-2001 CRISPR and silencer therapy
Polygenic risk scores: ancestry-aware ASCVD prediction
Clonal hematopoiesis (CHIP) as a CV risk modifier
Inherited arrhythmias: ACMG variant interpretation
DCM genotype-driven management: titin, lamin A/C, Danon

14 Track

Global Cardiovascular Health

Rheumatic heart disease, LMIC delivery, fixed-dose combinations and equity.

Track details

Rheumatic heart disease: WHF roadmap and Dig-RHD AI screening
Secondary penicillin prophylaxis and valve surgery in LMICs
Fixed-dose combination polypills (HOPE-3, TIPS-3)
Task-shifting CV care to community health workers
Hypertension control programs (May Measurement Month)
Chagas in non-endemic regions and migrant populations
Equity in clinical trial enrollment and guideline applicability

Have research aligned to one of these topics?

Submit your abstract by December 20, 2026. Oral and poster presentations are welcome across all 14 tracks.

Submit Abstract